Department of Dermatology

Guidelines for mouse and human DC functional assays (2022) Clausen BE, Amon L, Backer RA, Berod L, Bopp T, Brand A, Burgdorf S, et al. Journal article Guidelines for DC preparation and flow cytometric analysis of human lymphohematopoietic tissues (2022) Heger L, Dudziak D, Amon L, Hatscher L, Kaszubowski T, Lehmann C Journal article Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry (2022) Hanschmann T, Francuzik W, Doelle-Bierke S, Hofmeier KS, Grabenhenrich L, Rueff F, Renaudin JM, et al. Journal article eImmunonkologie: Development and Launch of a Virtual Education Platform for the Immunotherapy of Cutaneous Neoplasms (2022) Kaufmann M, Steeb T, Wessely A, Meyerolbersleben M, French LEE, Berking C, Heppt M Journal article Macrophage immunity and metabolism in cancer: Novel diagnostic and therapeutic strategies (2022) Leavenworth JW, Lai X, Miao H, Wang D, Zhao H, Li Y Journal article, Editorial Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML (2022) Fujii SI, Kawamata T, Shimizu K, Nakabayashi J, Yamasaki S, Iyoda T, Shinga J, et al. Journal article Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akcetin L, et al. Journal article Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study (2022) Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, et al. Journal article CHALLENGES OF NETWORK META-ANALYSIS FOR SAFETY OUTCOMES: THE ANALYSIS OF TIRBANIBULIN AGAINST COMMON TREATMENTS IN EUROPE FOR ACTINIC KERATOSIS (2022) Heppt M, Dykukha I, Chapman-Rounds M, Graziadio S, Edwards M Conference contribution ASSESSING SIMILARITY OF STUDIES FOR NETWORK META-ANALYSIS: THE USE OF FEASIBILITY ASSESSMENT AND SENSITIVITY ANALYSES TO ESTIMATE THE EFFICACY OF TIRBANIBULIN, A NEW DRUG FOR ACTINIC KERATOSIS (2022) Heppt M, Dykukha , Chapman-Rounds M, Graziadio S, Edwards M Conference contribution